EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma

Yanhong Zhang, Rosalia Rabinovsky, Evgeny Deforzh, Ami Kobayashi, Anastasia Kuzkina, Johnna Francis Varghese, Damita Rai, Joanna A Korecka, Vikram Khurana, Gopal Murugaiyan, David Morrissey, Erik J Uhlmann iD und 1 weitere

Neuro-Oncology · 01.11.2025 · 27 (11) · 2812-2827

DOI: 10.1093/neuonc/noaf162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.07.2025. Verfasst von Yanhong Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetta, U…. Hauptthemen laut MEDLINE: Glioblastoma, Nanoparticles, Brain Neoplasms, MicroRNAs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Brain Tumor Society, and StacheStrong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM), one of the deadliest cancers, resists current therapies, with drug development hindered by its high heterogeneity. However, GBM consistently relies on microRNA-10b (miR-10b), a key driver of glioma growth and a promising therapeutic target. miR-10b gene editing represents a potential treatment, but effective delivery strategies for gene editing systems in GBM remain unexplored.

Methods

We developed lipid nanoparticles (LNPs) encapsulating Cas9 mRNA and a miR-10b-targeting sgRNA (termed miRTEN). miRTEN was tested in glioma stem cells (GSCs) and orthotopic GBM models to assess therapeutic efficacy, immune responses, and safety.

Results

Intracerebroventricular injections of miRTEN enabled broad and durable Cas9 mRNA expression and miR-10b gene editing in tumor core and invasive areas across diverse GBM models. miRTEN significantly suppressed tumor growth, reduced GSC proliferation and viability, with therapeutic outcomes correlating with dose-dependent miR-10b suppression. Combining miRTEN with temozolomide (TMZ) further enhanced tumor suppression, overcoming TMZ resistance and improving survival. In immunocompetent models, miRTEN activated antitumor immune responses, increased cytotoxic CD8+ T cells infiltration, and promoted durable immune memory, enabling tumor rejection upon rechallenge. Safety assessments demonstrated that miRTEN selectively targets GBM cells, sparing normal brain tissues and causing no significant off-target toxicity.

Conclusion

As in vivo CRISPR-based drugs advance toward clinical applications, our findings demonstrate the potential of LNPs-mediated CRISPR–Cas9 systems for targeted miR-10b editing and, more generally, gene editing and RNA therapies for GBM. miRTEN monotherapy, as well as its combination with standard care, offers a promising, safe, and effective approach to improving outcomes in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNanoparticlesBrain NeoplasmsMicroRNAsGene EditingGenetic TherapyLipidsAnimalsHumansMiceXenograft Model Antitumor AssaysTemozolomideTumor Cells, CulturedCell ProliferationLiposomes

Stichwörter der Autor:innen

CRISPR–Cas9 | gene editingglioblastomalipid nanoparticlesmicroRNA-10b

Substanzen

MicroRNAsLipid NanoparticlesLipidsTemozolomideLiposomes

Autor:innen und Institutionen

  • Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetta, USA.
  • Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetta, USA.
  • Jumble Therapeutics, Cambridge, Massachusetta, USA.

ORCID-Profile: Erik J Uhlmann, Anna M Krichevsky

Förderung

  • NCI NIH HHS
  • National Brain Tumor Society, and StacheStrong

Zitieren

APA

Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J. F., Rai, D., Korecka, J. A., Khurana, V., Murugaiyan, G., Morrissey, D., Uhlmann, E. J., & Krichevsky, A. M. (2025). Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma. Neuro-Oncology, 27(11), 2812-2827. https://doi.org/10.1093/neuonc/noaf162

Vancouver

Zhang Y, Rabinovsky R, Deforzh E, Kobayashi A, Kuzkina A, Varghese JF, et al. Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma. Neuro-Oncology. 2025;27(11):2812-2827. doi:10.1093/neuonc/noaf162

BibTeX
@article{Zhang2025,
  author = {Zhang, Yanhong and Rabinovsky, Rosalia and Deforzh, Evgeny and Kobayashi, Ami and Kuzkina, Anastasia and Varghese, Johnna Francis and Rai, Damita and Korecka, Joanna A and Khurana, Vikram and Murugaiyan, Gopal and Morrissey, David and Uhlmann, Erik J and Krichevsky, Anna M},
  title = {Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {11},
  pages = {2812--2827},
  doi = {10.1093/neuonc/noaf162}
}
Kostenlos starten →